<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650973</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-1701-05</org_study_id>
    <nct_id>NCT02650973</nct_id>
  </id_info>
  <brief_title>Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta</brief_title>
  <official_title>A Randomized, Single-Blind, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess
      PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of
      CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of Neulasta (pegfilgrastim) given during each
      period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess
      PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of
      CHS-1701 or 6mg SC dose of Neulasta given during each period.

      The screening period may occur up to 28 days prior to the confinement period. After
      screening, eligible subjects will be randomly assigned to one of three possible treatment
      sequences. Treatments will be spaced by not less than 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence as measured by PK and PD</measure>
    <time_frame>84 Days</time_frame>
    <description>The primary objective of this study is to assess the bioequivalence of CHS-1701 with Neulasta® based on the pharmacokinetics (PK) of pegfilgrastim and the pharmacodynamic (PD) response as measured by absolute neutrophil count (ANC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Profile: Cmax</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the PK profile of CHS-1701 using standard parameters of maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile: tmax</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the PK profile of CHS-1701 using standard parameters of time to maximum plasma concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile: AUC0-t</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the PK profile of CHS-1701 using standard parameters of area under the plasma concentration versus time curve calculated from 0 to the last measurable observation (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile: t1/2</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the PK profile of CHS-1701 using standard parameters of terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs)</measure>
    <time_frame>84 Days</time_frame>
    <description>Characterization of the safety profile and tolerance of CHS-1701, as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of CHS-1701 or Neulasta, random order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of CHS-1701 or Neulasta, random order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of CHS-1701 or Neulasta, random order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHS-1701</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female of ages 18 to 45 inclusive

          2. Body weight &gt; 50 kg (110 lb.) and body mass index between 18 and 28 kg/m2 inclusive

          3. Medically healthy with clinically insignificant findings based on medical history,
             12-lead ECG, and physical examination

          4. Negative urine pregnancy test in women of childbearing potential

        Exclusion Criteria:

          1. Previous exposure to pegfilgrastim or filgrastim

          2. Current or previous cancer, diabetes, or any clinically significant cardiovascular,
             metabolic, endocrine, renal, hepatic, gastrointestinal, hematologic, respiratory,
             dermatological, neurological, gynecologic, psychiatric, or other disorder

          3. History of chronic or acute respiratory illness within the past 3 months

          4. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or
             recreational drugs for the duration of study participation

          5. No prescription or nonprescription drugs during the study

          6. Participation in an investigational clinical study within 30 days prior to screening

          7. History of known clinically significant drug and/or food allergies, including allergic
             reaction to latex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Finck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coherus BioSciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpace CPU</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaulding</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

